Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 17

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 17
---
 net proceeds from this offering for working capital and general corporate purposes. See “Use of Proceeds” on page 55 of this prospectus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| ​                                                 | ​ | ​                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Risk factors                                      |   | An investment in our securities involves a high degree of risk and could result in a loss of your entire investment. Prior to making an investment decision, you should carefully consider all of the information in this prospectus and, in particular, you should evaluate the risk factors set forth under the caption “Risk Factors” beginning on page 14.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| ​                                                 | ​ | ​                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Nasdaq Capital Market symbol                      |   | Our common stock is listed on the Nasdaq Capital Market under the symbol “MBIO”.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 ​There is no established public trading market for the Warrants and pre-funded warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Warrants or pre-funded warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants and pre-funded warrants will be limited.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

12

The number of shares of our common stock to be outstanding after this offering is based on 1,295,338 shares of our stock outstanding as of January 31, 2025, and excludes:

| ● | 1,521 shares of our common stock issuable upon the exercise of outstanding stock options as of January 31, 2025, with a weighted-average exercise price of $4,297.50 per share; |

| ● | 1,576,943 shares of our common stock issuable upon the exercise of outstanding warrants as of January 31, 2025, with a weighted-average exercise price of $14.56 per share; |

| ● | 1,127 shares of our common stock issuable upon conversion of the Class A Common Stock, at the holders’ election; |

| ● | 333 shares of our common stock issuable upon conversion of the Class A Preferred Stock, at the holders’ election; |

| ● | 6,946 shares of our common stock reserved for future issuance under the Mustang Bio, Inc. 2016 Equity Incentive Plan, as amended (